Dual-acting compounds targeting endocannabinoid and endovanilloid systems-a novel treatment option for chronic pain management

Frontiers in Pharmacology

Volumn 7, Issue AUG, 2016, Pages

  Malek, Natalia ^a   Starowicz, Katarzyna ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

COXs; Dual acting compounds; Endocannabinoid system; FAAH; Pain; TRPV1

Indexed keywords

2 [3 FLUORO 4 [3 (HEXYLCARBAMOYLOXY)PHENYL]PHENYL]PROPANOIC ACID; 3 [[(CHLORO)PYRIDIN 2 YL] 3 PHENYL] CARBAMATE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ENDOCANNABINOID; FATTY ACID AMIDASE; IBUPROFEN; N ARACHIDONOYL SEROTONIN; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; CHRONIC PAIN; DRUG DESIGN; ENTERITIS; ENZYME INHIBITION; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN TARGETING; SHORT SURVEY;

EID: 84988719541     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00257     Document Type: Short Survey

References (97)

1. Ahn, K., McKinney, M. K., and Cravatt, B. F. (2008). Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem. Rev. 108, 1687-1707. doi: 10.1021/cr0782067
2. Ahn, K., Smith, S. E., Liimatta, M. B., Beidler, D., Sadagopan, N., Dudley, D. T., et al. (2011). Mechanistic and pharmacological characterization of PF-04457845: a highly potent and selective fatty acid amide hydrolase inhibitor that reduces inflammatory and noninflammatory pain. J. Pharmacol. Exp. Ther. 338, 114-124. doi: 10.1124/jpet.111.180257
3. Aiello, F., Carullo, G., Badolato, M., and Brizzi, A. (2016). TRPV1-FAAH-COX: the couples game in pain treatment. ChemMedChem. doi: 10.1002/cmdc.201600111. [Epub ahead of print].
4. Altman, R. D. (2011). Safety advantages of topical versus oral nonsteroidal antiinflammatory drugs. J. Rheumatol. 38, 572-573. doi: 10.3899/jrheum.100748
5. Baamonde, A., Lastra, A., Juarez, L., Hidalgo, A., and Menéndez, L. (2005). TRPV1 desensitisation and endogenous vanilloid involvement in the enhanced analgesia induced by capsaicin in inflamed tissues. Brain Res. Bull. 67, 476-481. doi: 10.1016/j.brainresbull.2005.07.001
6. Bisogno, T., De Petrocellis, L., and Di Marzo, V. (2002). Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications. Curr. Pharm. Des. 8, 533-547. doi: 10.2174/1381612023395655
7. Bölcskei, K., Helyes, Z., Szabó, A., Sándor, K., Elekes, K., Németh, J., et al. (2005). Investigation of the role of TRPV1 receptors in acute and chronic nociceptive processes using gene-deficient mice. Pain 117, 368-376. doi: 10.1016/j.pain.2005.06.024
8. Bonica, J. J. (1979). The need of a taxonomy. Pain 6, 247-248. doi: 10.1016/0304-3959(79)90046-0
9. Boran, A. D. W., and Iyengar, R. (2010). Systems approaches to polypharmacology and drug discovery. Curr. Opin. Drug Discov. Devel. 13, 297-309.
10. Brodie, J. S., Di Marzo, V., and Guy, G. W. (2015). Polypharmacology shakes hands with complex aetiopathology. Trends Pharmacol. Sci. 36, 802-821. doi: 10.1016/j.tips.2015.08.010
11. Capasso, R., Matias, I., Lutz, B., Borrelli, F., Capasso, F., Marsicano, G., et al. (2005). Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 129, 941-951. doi: 10.1053/j.gastro.2005.06.018
12. Chang, L., Luo, L., Palmer, J. A., Sutton, S., Wilson, S. J., Barbier, A. J., et al. (2006). Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms. Br. J. Pharmacol. 148, 102-113. doi: 10.1038/sj.bjp.0706699
13. Costa, B., Bettoni, I., Petrosino, S., Comelli, F., Giagnoni, G., and Di Marzo, V. (2010). The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharmacol. Res. 61, 537-546. doi: 10.1016/j.phrs.2010.02.001
14. Cristino, L., De Petrocellis, L., Pryce, G., Baker, D., Guglielmotti, V., and Di Marzo, V. (2006). Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139, 1405-1415. doi: 10.1016/j.neuroscience.2006.02.074
15. Csermely, P., Agoston, V., and Pongor, S. (2005). The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 26, 178-182. doi: 10.1016/j.tips.2005.02.007
16. Davis, J. B., Gray, J., Gunthorpe, M. J., Hatcher, J. P., Davey, P. T., Overend, P., et al. (2000). Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405, 183-187. doi: 10.1038/35012076
17. De Lago, E., Petrosino, S., Valenti, M., Morera, E., Ortega-Gutierrez, S., Fernandez-Ruiz, J., et al. (2005). Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. Biochem. Pharmacol. 70, 446-452. doi: 10.1016/j.bcp.2005.05.011
18. De Novellis, V., Palazzo, E., Rossi, F., De Petrocellis, L., Petrosino, S., Guida, F., et al. (2008). The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 55, 1105-1113. doi: 10.1016/j.neuropharm.2008.06.023
19. De Novellis, V., Vita, D., Gatta, L., Luongo, L., Bellini, G., De Chiaro, M., et al. (2011). The blockade of the transient receptor potential vanilloid type 1 and fatty acid amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats. Mol. Pain 7:7. doi: 10.1186/1744-8069-7-7
20. De Petrocellis, L., Bisogno, T., Maccarrone, M., Davis, J. B., Finazzi-Agro, A., and Di Marzo, V. (2001). The activity of anandamide at vanilloid VR1 receptors requires facilitated transport across the cell membrane and is limited by intracellular metabolism. J. Biol. Chem. 276, 12856-12863. doi: 10.1074/jbc.M008555200
21. Deutsch, D. G., and Chin, S. A. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46, 791-796. doi: 10.1016/0006-2952(93)90486-G
22. Di Marzo, V. (2012). Inhibitors of endocannabinoid breakdown for pain: not so FA(AH)cile, after all. Pain 153, 1785-1786. doi: 10.1016/j.pain.2012.06.016
23. Di Marzo, V., Breivogel, C., Bisogno, T., Melck, D., Patrick, G., Tao, Q., et al. (2000). Neurobehavioral activity in mice of N-vanillyl-arachidonyl-amide. Eur. J. Pharmacol. 406, 363-374. doi: 10.1016/S0014-2999(00)00687-7
24. Di Marzo, V., and Petrosino, S. (2007). Endocannabinoids and the regulation of their levels in health and disease. Curr. Opin. Lipidol. 18, 129-140. doi: 10.1097/MOL.0b013e32803dbdec
25. Fowler, C. J. (2007). The contribution of cyclooxygenase-2 to endocannabinoid metabolism and action. Br. J. Pharmacol. 152, 594-601. doi: 10.1038/sj.bjp.0707379
26. Fowler, C. J., Janson, U., Johnson, R. M., Wahlström, G., Stenström, A., Norström, K., et al. (1999). Inhibition of anandamide hydrolysis by the enantiomers of ibuprofen, ketorolac, and flurbiprofen. Arch. Biochem. Biophys. 362, 191-196. doi: 10.1006/abbi.1998.1025
27. Fowler, C. J., Naidu, P. S., Lichtman, A., and Onnis, V. (2009). The case for the development of novel analgesic agents targeting both fatty acid amide hydrolase and either cyclooxygenase or TRPV1. Br. J. Pharmacol. 156, 412-419. doi: 10.1111/j.1476-5381.2008.00029.x
28. Fowler, C. J., Tiger, G., López-Rodríguez, M. L., Viso, A., Ortega-Gutiérrez, S., and Ramos, J. A. (2003). Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. J. Enzyme Inhib. Med. Chem. 18, 225-231. doi: 10.1080/1475636031000080216
29. Gallagher, R. M., and Rosenthal, L. J. (2008). Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment. Arch. Phys. Med. Rehabil. 89, S77-S82. doi: 10.1016/j.apmr.2007.12.003
30. Gavva, N. R., Treanor, J. J. S., Garami, A., Fang, L., Surapaneni, S., Akrami, A., et al. (2008). Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 136, 202-210. doi: 10.1016/j.pain.2008.01.024
31. Grim, T. W., Ghosh, S., Hsu, K.-L., Cravatt, B. F., Kinsey, S. G., and Lichtman, A. H. (2014). Combined inhibition of FAAH and COX produces enhanced anti-allodynic effects in mouse neuropathic and inflammatory pain models. Pharmacol. Biochem. Behav. 124, 405-411. doi: 10.1016/j.pbb.2014.07.008
32. Guindon, J., and Beaulieu, P. (2006). Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxib and their combinations in a model of neuropathic pain. Neuropharmacology 50, 814-823. doi: 10.1016/j.neuropharm.2005.12.002
33. Guindon, J., De Léan, A., and Beaulieu, P. (2006). Local interactions between anandamide, an endocannabinoid, and ibuprofen, a nonsteroidal anti-inflammatory drug, in acute and inflammatory pain. Pain 121, 85-93. doi: 10.1016/j.pain.2005.12.007
34. Guindon, J., and Hohmann, A. G. (2008). A physiological role for endocannabinoid-derived products of cyclooxygenase-2-mediated oxidative metabolism. Br. J. Pharmacol. 153, 1341-1343. doi: 10.1038/bjp.2008.41
35. Guindon, J., Lai, Y., Takacs, S. M., Bradshaw, H. B., and Hohmann, A. G. (2013). Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. Pharmacol. Res. 67, 94-109. doi: 10.1016/j.phrs.2012.10.013
36. Holt, S., Comelli, F., Costa, B., and Fowler, C. J. (2005). Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: comparison with indomethacin and possible involvement of cannabinoid receptors. Br. J. Pharmacol. 146, 467-476. doi: 10.1038/sj.bjp.0706348
37. Horvath, G., Kekesi, G., Nagy, E., and Benedek, G. (2008). The role of TRPV1 receptors in the antinociceptive effect of anandamide at spinal level. Pain 134, 277-284. doi: 10.1016/j.pain.2007.04.032
38. Hu, S. S.-J., Bradshaw, H. B., Chen, J. S.-C., Tan, B., and Walker, J. M. (2008). Prostaglandin E2 glycerol ester, an endogenous COX-2 metabolite of 2-arachidonoylglycerol, induces hyperalgesia and modulates NFkappaB activity. Br. J. Pharmacol. 153, 1538-1549. doi: 10.1038/bjp.2008.33
39. Huggins, J. P., Smart, T. S., Langman, S., Taylor, L., and Young, T. (2012). An efficient randomised, placebo-controlled clinical trial with the irreversible fatty acid amide hydrolase-1 inhibitor PF-04457845, which modulates endocannabinoids but fails to induce effective analgesia in patients with pain due to osteoarthritis of the knee. Pain 153, 1837-1846. doi: 10.1016/j.pain.2012.04.020
40. Huwiler, A., and Pfeilschifter, J. (2009). Lipids as targets for novel anti-inflammatory therapies. Pharmacol. Ther. 124, 96-112. doi: 10.1016/j.pharmthera.2009.06.008
41. Hwang, S. H., Wecksler, A. T., Wagner, K., and Hammock, B. D. (2013). Rationally Designed Multitarget Agents Against Inflammation and Pain. Curr. Med. Chem. 20, 1783-1799. doi: 10.2174/0929867311320130013
42. Ikeda-Miyagawa, Y., Kobayashi, K., Yamanaka, H., Okubo, M., Wang, S., Dai, Y., et al. (2015). Peripherally increased artemin is a key regulator of TRPA1/V1 expression in primary afferent neurons. Mol. Pain 8, 8-11. doi: 10.1186/s12990-015-0004-7
43. Immke, D. C., and Gavva, N. R. (2006). The TRPV1 receptor and nociception. Semin. Cell Dev. Biol. 17, 582-591. doi: 10.1016/j.semcdb.2006.09.004
44. Ito, S., Okuda-Ashitaka, E., and Minami, T. (2001). Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci. Res. 41, 299-332. doi: 10.1016/S0168-0102(01)00289-9
45. Jayamanne, A., Greenwood, R., Mitchell, V. A., Aslan, S., Piomelli, D., and Vaughan, C. W. (2006). Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br. J. Pharmacol. 147, 281-288. doi: 10.1038/sj.bjp.0706510
46. Jhaveri, M. D., Richardson, D., and Chapman, V. (2007). Endocannabinoid metabolism and uptake: novel targets for neuropathic and inflammatory pain. Br. J. Pharmacol. 152, 624-632. doi: 10.1038/sj.bjp.0707433
47. Jhaveri, M. D., Richardson, D., Kendall, D. A., Barrett, D. A., and Chapman, V. (2006). Analgesic effects of fatty acid amide hydrolase inhibition in a rat model of neuropathic pain. J. Neurosci. 26, 13318-13327. doi: 10.1523/JNEUROSCI.3326-06.2006
48. Jhaveri, M. D., Richardson, D., Robinson, I., Garle, M. J., Patel, A., Sun, Y., et al. (2008). Inhibition of fatty acid amide hydrolase and cyclooxygenase-2 increases levels of endocannabinoid related molecules and produces analgesia via peroxisome proliferator-activated receptor-alpha in a model of inflammatory pain. Neuropharmacology 55, 85-93. doi: 10.1016/j.neuropharm.2008.04.018
49. Kanai, Y., Hara, T., and Imai, A. (2006). Participation of the spinal TRPV1 receptors in formalin-evoked pain transduction: a study using a selective TRPV1 antagonist, iodo-resiniferatoxin. J. Pharm. Pharmacol. 58, 489-493. doi: 10.1211/jpp.58.4.0008
50. Karai, L., Brown, D. C., Mannes, A. J., Connelly, S. T., Brown, J., Gandal, M., et al. (2004). Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J. Clin. Invest. 113, 1344-1352. doi: 10.1172/JCI20449
51. Khanna, I. K., and Alexander, C. W. (2011). Fatty acid amide hydrolase inhibitors-progress and potential. CNS Neurol. Disord. Drug Targets 10, 545-558. doi: 10.2174/187152711796234989
52. Kinsey, S. G., Long, J. Z., O'Neal, S. T., Abdullah, R. A., Poklis, J. L., Boger, D. L., et al. (2009). Blockade of endocannabinoid-degrading enzymes attenuates neuropathic pain. J. Pharmacol. Exp. Ther. 330, 902-910. doi: 10.1124/jpet.109.155465
53. Kozak, K. R., Crews, B. C., Morrow, J. D., Wang, L.-H., Ma, Y. H., Weinander, R., et al. (2002). Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides. J. Biol. Chem. 277, 44877-44885. doi: 10.1074/jbc.M206788200
54. La Porta, C., Bura, S. A., Aracil-Fernández, A., Manzanares, J., and Maldonado, R. (2013). Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate. Pain 154, 160-174. doi: 10.1016/j.pain.2012.10.009
55. Lee, Y., Hong, S., Cui, M., Sharma, P. K., Lee, J., and Choi, S. (2015). Transient receptor potential vanilloid type 1 antagonists: a patent review (2011-2014). Expert Opin. Ther. Pat. 25, 291-318. doi: 10.1517/13543776.2015.1008449
56. Lichtman, A. H., and Chapman, V. (2011). A FAAH-fetched approach to treat osteoarthritis pain. Pain 152, 959-960. doi: 10.1016/j.pain.2011.02.034
57. Lichtman, A. H., Leung, D., Shelton, C. C., Saghatelian, A., Hardouin, C., Boger, D. L., et al. (2004). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther. 311, 441-448. doi: 10.1124/jpet.104.069401
58. Lizanecz, E., Bagi, Z., Pásztor, E. T., Papp, Z., Edes, I., Kedei, N., et al. (2006). Phosphorylation-dependent desensitization by anandamide of vanilloid receptor-1 (TRPV1) function in rat skeletal muscle arterioles and in Chinese hamster ovary cells expressing TRPV1. Mol. Pharmacol. 69, 1015-1023. doi: 10.1124/mol.105.015644
59. Lomazzo, E., Bindila, L., Remmers, F., Lerner, R., Schwitter, C., Hoheisel, U., et al. (2015). Therapeutic potential of inhibitors of endocannabinoid degradation for the treatment of stress-related hyperalgesia in an animal model of chronic pain. Neuropsychopharmacology 40, 488-501. doi: 10.1038/npp.2014.198
60. Maione, S., Bisogno, T., De Novellis, V., Palazzo, E., Cristino, L., Valenti, M., et al. (2006). Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 316, 969-982. doi: 10.1124/jpet.105.093286
61. Maione, S., Costa, B., Piscitelli, F., Morera, E., De Chiaro, M., Comelli, F., et al. (2013). Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics. Pharmacol. Res. 76, 98-105. doi: 10.1016/j.phrs.2013.07.003
62. Maione, S., De Petrocellis, L., De Novellis, V., Moriello, A. S., Petrosino, S., Palazzo, E., et al. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 150, 766-781. doi: 10.1038/sj.bjp.0707145
63. Malek, N., Kostrzewa, M., Makuch, W., Pajak, A., Kucharczyk, M., Piscitelli, F., et al. (2016). The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain. Pharmacol. Res. 111, 251-263. doi: 10.1016/j.phrs.2016.06.012
64. Malek, N., Mrugala, M., Makuch, W., Kolosowska, N., Przewlocka, B., Binkowski, M., et al. (2015a). A multi-target approach for pain treatment-dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis. Pain. 156, 890-903. doi: 10.1097/j.pain.0000000000000132
65. Malek, N., Popiolek-Barczyk, K., Mika, J., Przewlocka, B., and Starowicz, K. (2015b). Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plast. 2015:130639. doi: 10.1155/2015/130639
66. Mecha, M., Feliú, A., Carrillo-Salinas, F. J., Rueda-Zubiaurre, A., Ortega-Gutiérrez, S., De Sola, R. G., et al. (2015). Endocannabinoids drive the acquisition of an alternative phenotype in microglia. Brain Behav. Immun. 49, 233-245. doi: 10.1016/j.bbi.2015.06.002
67. Migliore, M., Habrant, D., Sasso, O., Albani, C., Bertozzi, S. M., Armirotti, A., et al. (2016). Potent multitarget FAAH-COX inhibitors: design and structure-activity relationship studies. Eur. J. Med. Chem. 109, 216-237. doi: 10.1016/j.ejmech.2015.12.036
68. Morera, E., De Petrocellis, L., Morera, L., Moriello, A. S., Ligresti, A., Nalli, M., et al. (2009). Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands. Bioorg. Med. Chem. Lett. 19, 6806-6809. doi: 10.1016/j.bmcl.2009.09.033
69. Morera, E., Di Marzo, V., Monti, L., Allarà, M., Schiano Moriello, A., Nalli, M., et al. (2016). Arylboronic acids as dual-action FAAH and TRPV1 ligands. Bioorg. Med. Chem. Lett. 26, 1401-1405. doi: 10.1016/j.bmcl.2016.01.071
70. Naidu, P. S., Kinsey, S. G., Guo, T. L., Cravatt, B. F., and Lichtman, A. H. (2010). Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. J. Pharmacol. Exp. Ther. 334, 182-190. doi: 10.1124/jpet.109.164806
71. Okine, B. N., Norris, L. M., Woodhams, S., Burston, J., Patel, A., Alexander, S. P., et al. (2012). Lack of effect of chronic pre-treatment with the FAAH inhibitor URB597 on inflammatory pain behaviour: evidence for plastic changes in the endocannabinoid system. Br. J. Pharmacol. 167, 627-640. doi: 10.1111/j.1476-5381.2012.02028.x
72. Ortar, G., Cascio, M. G., De Petrocellis, L., Morera, E., Rossi, F., Schiano-Moriello, A., et al. (2007). New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain. J. Med. Chem. 50, 6554-6569. doi: 10.1021/jm070678q
73. Ortar, G., De Petrocellis, L., Moriello, A. S., Allarà, M., Morera, E., Nalli, M., et al. (2013). Tetrahydro-β-carboline derivatives targeting fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channels. Bioorg. Med. Chem. Lett. 23, 138-142. doi: 10.1016/j.bmcl.2012.10.137
74. Paylor, B., Holt, S., and Fowler, C. J. (2006). The potency of the fatty acid amide hydrolase inhibitor URB597 is dependent upon the assay pH. Pharmacol. Res. 54, 481-485. doi: 10.1016/j.phrs.2006.07.006
75. Pernía-Andrade, A. J., Kato, A., Witschi, R., Nyilas, R., Katona, I., Freund, T. F., et al. (2009). Spinal endocannabinoids and CB1 receptors mediate C-fiber-induced heterosynaptic pain sensitization. Science 325, 760-764. doi: 10.1126/science.1171870
76. Piomelli, D., and Sasso, O. (2014). Peripheral gating of pain signals by endogenous lipid mediators. Nat. Neurosci. 17:1287. doi: 10.1038/nn0914-1287d
77. Piscitelli, F., and Di Marzo, V. (2012). "Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem. Neurosci. 3, 356-363. doi: 10.1021/cn300015x
78. Rahme, E., and Bernatsky, S. (2010). NSAIDs and risk of lower gastrointestinal bleeding. Lancet 376, 146-148. doi: 10.1016/S0140-6736(10)60839-2
79. Ray, W. A., Chung, C. P., Stein, C. M., Smalley, W. E., Hall, K., Arbogast, P. G., et al. (2007). Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs. Gastroenterology 133, 790-798. doi: 10.1053/j.gastro.2007.06.058
80. Richardson, J. D., Kilo, S., and Hargreaves, K. M. (1998). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75, 111-119. doi: 10.1016/S0304-3959(97)00213-3
81. Roberts, J. C., Davis, J. B., and Benham, C. D. (2004). [3H]Resiniferatoxin autoradiography in the CNS of wild-type and TRPV1 null mice defines TRPV1 (VR-1) protein distribution. Brain Res. 995, 176-183. doi: 10.1016/j.brainres.2003.10.001
82. Sasso, O., Migliore, M., Habrant, D., Armirotti, A., Albani, C., Summa, M., et al. (2015). Multitarget fatty acid amide hydrolase/cyclooxygenase blockade suppresses intestinal inflammation and protects against nonsteroidal anti-inflammatory drug-dependent gastrointestinal damage. FASEB J. 29, 2616-2627. doi: 10.1096/fj.15-270637
83. Seidel, K., Hamza, M., Ates, M., and Gühring, H. (2003). Flurbiprofen inhibits capsaicin induced calcitonin gene related peptide release from rat spinal cord via an endocannabinoid dependent mechanism. Neurosci. Lett. 338, 99-102. doi: 10.1016/S0304-3940(02)01366-6
84. Singh Tahim, A., Sántha, P., and Nagy, I. (2005). Inflammatory mediators convert anandamide into a potent activator of the vanilloid type 1 transient receptor potential receptor in nociceptive primary sensory neurons. Neuroscience 136, 539-548. doi: 10.1016/j.neuroscience.2005.08.005
85. Smith, W. L., Garavito, R. M., and DeWitt, D. L. (1996). Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and-2. J. Biol. Chem. 271, 33157-33160. doi: 10.1074/jbc.271.52.33157
86. Stahl, S. M. (2009). Multifunctional drugs: a novel concept for psychopharmacology. CNS Spectr. 14, 71-73. doi: 10.1017/S1092852900000213
87. Starowicz, K., and Di Marzo, V. (2013). Non-psychotropic analgesic drugs from the endocannabinoid system: "magic bullet" or "multiple-target" strategies? Eur. J. Pharmacol. 716, 41-53. doi: 10.1016/j.ejphar.2013.01.075
88. Starowicz, K., Maione, S., Cristino, L., Palazzo, E., Marabese, I., Rossi, F., et al. (2007). Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci. 27, 13739-13749. doi: 10.1523/JNEUROSCI.3258-07.2007
89. Starowicz, K., Makuch, W., Korostynski, M., Malek, N., Slezak, M., Zychowska, M., et al. (2013). Full inhibition of spinal FAAH leads to TRPV1-mediated analgesic effects in neuropathic rats and possible lipoxygenase-mediated remodeling of anandamide metabolism. PLoS ONE 8:e60040. doi: 10.1371/journal.pone.0060040
90. Swanson, D. M., Dubin, A. E., Shah, C., Nasser, N., Chang, L., Dax, S. L., et al. (2005). Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J. Med. Chem. 48, 1857-1872. doi: 10.1021/jm0495071
91. Thaler, A., Gupta, A., and Cohen, S. P. (2011). Cannabinoids for pain management. Adv. Psychosom. Med. 30, 125-138. doi: 10.1159/000324070
92. Toth, C. C., Jedrzejewski, N. M., Ellis, C. L., and Frey, W. H. II. (2010). Cannabinoid-mediated modulation of neuropathic pain and microglial accumulation in a model of murine type I diabetic peripheral neuropathic pain. Mol. Pain 6:16. doi: 10.1186/1744-8069-6-16
93. Ulugöl, A., Ozyigit, F., Yesilyurt, O., and Dogrul, A. (2006). The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac. Anesth. Analg. 102, 443-447. doi: 10.1213/01.ane.0000194587.94260.1d
94. Van der Stelt, M., Trevisani, M., Vellani, V., De Petrocellis, L., Schiano Moriello, A., Campi, B., et al. (2005). Anandamide acts as an intracellular messenger amplifying Ca2+ influx via TRPV1 channels. EMBO J. 24, 3026-3037. doi: 10.1038/sj.emboj.7600784
95. Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., Von Zastrow, M., Schulz, S., et al. (2013). Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol. Rev. 65, 223-254. doi: 10.1124/pr.112.005942
96. Yang, W., Ni, J., Woodward, D. F., Tang-Liu, D. D.-S., and Ling, K.-H. J. (2005). Enzymatic formation of prostamide F2alpha from anandamide involves a newly identified intermediate metabolite, prostamide H2. J. Lipid Res. 46, 2745-2751. doi: 10.1194/jlr.M500374-JLR200
97. Zygmunt, P. M., Petersson, J., Andersson, D. A., Chuang, H., Sørgård, M., Di Marzo, V., et al. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457. doi: 10.1038/22761